Life Technologies

Life Technologies Parkinson’s disease cell models—part 3

Issue link: http://life-technologies.uberflip.com/i/368629

Contents of this Issue

Navigation

Page 18 of 33

19 Life Technologies ™ | lifetechnologies.com/parkinsons To establish cell models to study the contribution of α-synuclein deposits to other PD-relevant phenotypes, we used GeneArt ® Precision TALs to generate cell lines with either a single copy or both copies of the SNCA gene deleted. A TAL pair was designed to bind to exon 2 of SNCA, targeting the start site of translation (Figure 7A). The TAL pair was electroporated into the MSA donor iPSCs, and the cells were plated onto a MEF feeder layer for recovery. Out of 12 screened colonies, two were identified as positive by the GeneArt ® Genomic Cleavage Detection assay (Figure 7B), which were further confirmed by Sanger sequencing (data not shown). One colony (colony 21) contained a population of cells with a 2 bp deletion in codon 4 on one allele, which results in a frameshift mutation that introduces a stop codon after an 18 amino acid peptide. Another colony (colony 30) had a 12 bp, in-frame deletion in one allele, so the resulting protein would contain only a 4 amino acid deletion in its protein sequence (unsuitable for our purposes). Colony 21 was further subcloned, and daughter colonies were again screened by the cleavage detection assay (data not shown). Generation of α-synuclein knockout lines from the MSA line Figure 7. Colony screening by GeneArt ® Genomic Cleavage Detection Kit. (A) SNCA TAL pair binding sites. (B) Genomic DNA was prepared from recovered iPSC colonies, followed by a nested PCR over the SNCA region to be edited. The PCR product (~400 bp) was denatured and re-annealed. If editing occurred, heteroduplexes were formed, which were cleaved. Lanes lacking cleavage enzyme are shown with a minus symbol (–) and lanes that were treated with cleavage enzyme are shown with a plus symbol (+). Samples from colonies 21 and 30 have clearly visible cleavage products with desired sizes, indicating the presence of a mismatch as a result of a TAL editing event. A B 340 350 290 300 310 320 330 Targeting exon 2 of SNCA Forward SNCA TAL Reverse SNCA TAL GTGGTGTA A AGGA ATTCATTAGCATGGATGTATTCATGA A AGGACTTTCA A AGGCCA AGGGAGTT Results 10 21 25 30 5 - + - + - + - + - +

Articles in this issue

Links on this page

view archives of Life Technologies - Life Technologies Parkinson’s disease cell models—part 3